Phio Pharmaceuticals (PHIO) Competitors $1.77 -0.06 (-3.06%) Closing price 03:58 PM EasternExtended Trading$1.84 +0.07 (+3.72%) As of 04:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PHIO vs. SPRO, LVTX, COEP, FBLG, DYAI, BLUE, KZR, FGEN, MRNS, and INKTShould you be buying Phio Pharmaceuticals stock or one of its competitors? The main competitors of Phio Pharmaceuticals include Spero Therapeutics (SPRO), LAVA Therapeutics (LVTX), Coeptis Therapeutics (COEP), FibroBiologics (FBLG), Dyadic International (DYAI), bluebird bio (BLUE), Kezar Life Sciences (KZR), FibroGen (FGEN), Marinus Pharmaceuticals (MRNS), and MiNK Therapeutics (INKT). These companies are all part of the "pharmaceutical products" industry. Phio Pharmaceuticals vs. Spero Therapeutics LAVA Therapeutics Coeptis Therapeutics FibroBiologics Dyadic International bluebird bio Kezar Life Sciences FibroGen Marinus Pharmaceuticals MiNK Therapeutics Spero Therapeutics (NASDAQ:SPRO) and Phio Pharmaceuticals (NASDAQ:PHIO) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, media sentiment, dividends, community ranking, earnings, valuation and risk. Is SPRO or PHIO more profitable? Spero Therapeutics has a net margin of 3.30% compared to Phio Pharmaceuticals' net margin of 0.00%. Spero Therapeutics' return on equity of 4.03% beat Phio Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Spero Therapeutics3.30% 4.03% 2.21% Phio Pharmaceuticals N/A -134.57%-108.39% Which has more risk & volatility, SPRO or PHIO? Spero Therapeutics has a beta of 0.23, indicating that its stock price is 77% less volatile than the S&P 500. Comparatively, Phio Pharmaceuticals has a beta of 0.99, indicating that its stock price is 1% less volatile than the S&P 500. Does the media favor SPRO or PHIO? In the previous week, Spero Therapeutics and Spero Therapeutics both had 1 articles in the media. Phio Pharmaceuticals' average media sentiment score of 1.00 beat Spero Therapeutics' score of 0.00 indicating that Phio Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Spero Therapeutics Neutral Phio Pharmaceuticals Positive Which has better earnings and valuation, SPRO or PHIO? Spero Therapeutics has higher revenue and earnings than Phio Pharmaceuticals. Spero Therapeutics is trading at a lower price-to-earnings ratio than Phio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSpero Therapeutics$28.30M1.35$22.81M-$1.28-0.54Phio PharmaceuticalsN/AN/A-$10.83M-$10.92-0.16 Does the MarketBeat Community prefer SPRO or PHIO? Spero Therapeutics received 171 more outperform votes than Phio Pharmaceuticals when rated by MarketBeat users. Likewise, 69.67% of users gave Spero Therapeutics an outperform vote while only 64.41% of users gave Phio Pharmaceuticals an outperform vote. CompanyUnderperformOutperformSpero TherapeuticsOutperform Votes20969.67% Underperform Votes9130.33% Phio PharmaceuticalsOutperform Votes3864.41% Underperform Votes2135.59% Do analysts rate SPRO or PHIO? Spero Therapeutics currently has a consensus price target of $5.00, suggesting a potential upside of 629.08%. Phio Pharmaceuticals has a consensus price target of $4.00, suggesting a potential upside of 125.48%. Given Spero Therapeutics' higher possible upside, equities research analysts plainly believe Spero Therapeutics is more favorable than Phio Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Spero Therapeutics 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50Phio Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals have more ownership in SPRO or PHIO? 25.6% of Spero Therapeutics shares are held by institutional investors. Comparatively, 57.3% of Phio Pharmaceuticals shares are held by institutional investors. 4.5% of Spero Therapeutics shares are held by insiders. Comparatively, 0.6% of Phio Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. SummarySpero Therapeutics beats Phio Pharmaceuticals on 12 of the 16 factors compared between the two stocks. Get Phio Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PHIO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PHIO vs. The Competition Export to ExcelMetricPhio PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.48M$6.49B$5.36B$8.39BDividend YieldN/A2.66%5.22%4.10%P/E Ratio-0.168.9426.5919.72Price / SalesN/A251.55391.61116.20Price / CashN/A65.8538.2534.62Price / Book0.106.466.794.51Net Income-$10.83M$143.98M$3.23B$248.18M7 Day Performance-4.62%3.16%4.03%1.14%1 Month Performance-37.31%7.60%12.22%15.07%1 Year Performance-74.06%-2.36%16.76%6.59% Phio Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PHIOPhio Pharmaceuticals3.1463 of 5 stars$1.77-3.1%$4.00+125.5%-74.1%$8.48MN/A-0.1610Positive NewsSPROSpero Therapeutics4.3538 of 5 stars$0.61-1.6%$5.00+719.7%-56.4%$34.11M$27.40M8.72150LVTXLAVA Therapeutics2.2336 of 5 stars$1.28+2.3%$3.17+147.6%-51.1%$33.64M$11.98M-1.2460Positive NewsEarnings ReportAnalyst RevisionCOEPCoeptis Therapeutics0.6986 of 5 stars$9.90+4.2%N/A+45.2%$33.31MN/A-1.712Positive NewsEarnings ReportFBLGFibroBiologics1.5731 of 5 stars$0.87+4.7%$13.00+1,394.3%-91.7%$33.29MN/A-2.5610DYAIDyadic International2.2941 of 5 stars$1.10+2.8%$6.00+445.5%-34.3%$33.10M$3.50M-4.787Positive NewsEarnings ReportBLUEbluebird bio2.7446 of 5 stars$3.29-6.0%$44.60+1,255.6%-75.8%$32.21M$83.81M-0.09520High Trading VolumeKZRKezar Life Sciences4.2212 of 5 stars$4.23+0.2%$39.50+833.8%-46.6%$30.90M$7M-0.3260FGENFibroGen4.4121 of 5 stars$0.31-0.8%$10.00+3,174.4%-71.3%$30.86M$29.62M-0.25570MRNSMarinus Pharmaceuticals1.8985 of 5 stars$0.55-0.2%$4.79+771.6%-59.3%$30.32M$30.99M-0.22110News CoverageAnalyst ForecastINKTMiNK Therapeutics2.6544 of 5 stars$7.60+8.1%$37.50+393.4%-26.1%$30.14MN/A-1.9530Earnings ReportAnalyst RevisionGap Up Related Companies and Tools Related Companies SPRO Competitors LVTX Competitors COEP Competitors FBLG Competitors DYAI Competitors BLUE Competitors KZR Competitors FGEN Competitors MRNS Competitors INKT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PHIO) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Phio Pharmaceuticals Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Phio Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PHIO Stock Free PHIO Stock Alerts